Previous efforts to develop anti-melanoma ADCs include DEDN6526A (Seattle Genetics/Genentech) [13] targeted to the endothelin B receptor (ETBR) and glembatumumab vedotin (Celldex) [14] recognizing the transmembrane glycoprotein NMB (GPNMB), both carrying the antimitotic payload monomethyl auristatin E (MMAE, vedotin). This evidence concerns the gene GPNMB and melanoma.